Plain-English translation of NCT06725693 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging technology called 68Ga/18F-Exendin 4 PET/CT that helps doctors find and track tumors related to GLP-1 receptors in the body. The medication is injected into your bloodstream, and then a special scanner takes detailed pictures to show where these tumors might be located. Researchers want to understand how accurate this imaging method is compared to other ways of finding these tumors.
Some tumors produce hormones linked to GLP-1 receptors, but they can be hard to find with standard imaging tools like CT or MRI scans. This trial exists to see whether this specialized imaging can help doctors spot these tumors more reliably and earlier, which could improve diagnosis and treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the imaging medication into your vein. After the injection, you will wait a specified amount of time and then undergo a PET/CT scan, which involves lying still on a table while a machine takes detailed pictures of your body. The entire process typically takes a few hours. This is a one-time imaging procedure—there are no ongoing visits or long-term commitments.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China
Collaborators
Tianjin Medical University General Hospital
Enrollment target
~500 participants
Started
February 2019
Primary completion
November 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Qiusong Chen, MD
Tianjin Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.